A novel super-enhancer-related risk model for predicting prognosis and guiding personalized treatment in hepatocellular carcinoma
We developed a novel HCC prognostic model utilizing SERGs, indicating that patients with high-risk score not only face a poorer prognosis but also may exhibit a diminished therapeutic response to immune checkpoint inhibitors (ICIs). This model is designed to tailor personalized treatment strategies to the individual needs of each patient, thereby improving the overall clinical outcomes for HCC patients. Furthermore, CBX2 is a promising candidate for therapeutic intervention in HCC.
Authors
- Binbin Mao (ORCID: https://orcid.org/0000-0002-4811-6374)
- Nan Lin (ORCID: https://orcid.org/0000-0002-4635-3966)
- Xianhe Xie (ORCID: https://orcid.org/0000-0002-4134-5887)
- Ping Li (ORCID: https://orcid.org/0000-0003-0958-6784)
- Xuan Tao (ORCID: https://orcid.org/0009-0003-6244-7852)
- Qing Wu
Institutions
- Fujian Medical University (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1186/s12885-024-12874-7
- Citations
- 3
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- Natural Science Foundation of Fujian Province